Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoGenex Pharmaceuticals, Inc. on April 27, 2015, with the earliest event reported on April 30, 2015. The filing details the entry into a new material definitive agreement for a registered offering of securities and the termination of a prior sales agreement.
Key Financial Metrics and Transaction Details
- Registered Offering: The Company entered into a Purchase Agreement with Lincoln Park Capital Fund, LLC (LPC) to sell up to $18,000,000 in common stock over a 24-month term.
- Initial Purchase: LPC is obligated to initially purchase $2,000,000 of Series A-1 Units (one share of common stock plus one warrant to purchase 1/4 share at $2.40).
- Additional Purchases: The Company may direct LPC to purchase up to an additional $16,000,000 of common stock at prevailing market prices without a fixed discount.
- Issuance for Consideration: The Company issued 126,582 shares of common stock to LPC as consideration for entering the agreement; no cash proceeds were received for these specific shares.
- Placement Agent Fees: Academy Securities, Inc. will receive $10,000 in compensation plus reimbursement of up to $5,000 in out-of-pocket expenses, subject to FINRA approval.
- Use of Proceeds: Proceeds are intended to advance proprietary product candidates (custirsen and apatorsen), general corporate purposes, and potentially pre-clinical assets or acquisitions.
- Financial Statements: This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes Versus Prior Period
- Termination of ATM Offering: The Company terminated its "at the market" (ATM) equity offering program with MLV & Co. LLC, which was originally established on June 18, 2013, with a $25,000,000 aggregate sales limit. No termination penalties were incurred.
- Capital Structure Change: The new agreement replaces the previous ATM mechanism with a direct purchase agreement allowing the Company to control the timing and amount of sales, subject to market price conditions (e.g., accelerated purchases if the closing price is not below $1.50).
Guidance, Outlook, and Risks
- Outlook: Management intends to use the offering to fund clinical trial developments for custirsen and apatorsen.
- Risks and Contingencies: The filing includes forward-looking statements subject to risks regarding the successful completion of the offering, clinical trial success, and general economic conditions. The Company undertakes no obligation to update these statements.
- Unusual Items: The initial purchase includes warrants exercisable six months after issuance for a five-year and six-month term. No warrants will be issued for subsequent purchases under the agreement.
Important Facts for Investor Verification
- Verify the closing of the initial $2,000,000 purchase and the issuance of Series A-1 Units on or around April 30, 2015.
- Confirm FINRA's determination regarding the fairness of the Purchase Agreement terms to ensure the $10,000 placement agent fee is payable.
- Monitor the Company's ability to direct purchases under the new agreement, noting the requirement that the closing sale price must not be below $1.50 per share for accelerated purchases.
- Review the impact of the 126,582 shares issued as consideration on existing shareholder dilution.
- Check subsequent filings for updates on the clinical progress of custirsen and apatorsen funded by these proceeds.